Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-26.2%
5Y CAGR-20.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-26.2%/yr
vs -8.7%/yr prior
5Y CAGR
-20.1%/yr
Recent deceleration
Acceleration
-17.4pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $47.85M | +3.5% |
| 2024 | $46.24M | -46.3% |
| 2023 | $86.11M | -27.6% |
| 2022 | $118.93M | +12.2% |
| 2021 | $105.97M | -27.9% |
| 2020 | $146.94M | -16.3% |
| 2019 | $175.61M | +2.4% |
| 2018 | $171.49M | +16.2% |
| 2017 | $147.60M | +155.1% |
| 2016 | $57.87M | - |